ErbB2/Her2 anticorps (Alexa Fluor 647)

N° du produit ABIN2657764

L’anticorps Souris Monoclonal anti-ErbB2/Her2 a été validé pour FACS. Il convient pour détecter ErbB2/Her2 dans des échantillons de Humain.

Aperçu rapide pour ErbB2/Her2 anticorps (Alexa Fluor 647) (ABIN2657764)

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ErbB2/Her2 est conjugé à/à la Alexa Fluor 647

Application: Flow Cytometry (FACS)

Clone: 24D2

Détail du produit anti-ErbB2/Her2 anticorps (Alexa Fluor 647)

Purification: The antibody was purified by affinity chromatography, and conjugated with Alexa Fluor® 647 under optimal conditions.

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C

Détails sur ErbB2/Her2

Antigène: ErbB2/Her2 (Receptor tyrosine-protein kinase erbB-2 (ErbB2/Her2))

Autre désignation: CD340

Sujet: CD340 is also known as HER2/erbB2, tyrosine kinase cell surface receptor HER2, oncogene ERBB2, and oncogene NGL, neuroblastoma- or glioblastoma-derived. It is a member of the epidermal growth factor receptor family of cell membrane tyrosine kinases containing a single transmembrane domain and has an approximate molecular weight of 185 kD. CD340 contains three furin repeats and two cheY homologous receiver domains in the extracellular region (ECR). The HER2/erbB2 protein is expressed on many tumor cells, including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow mesenchymal stem cells. Although the erbB2/HER2 protein contains no ligand binding domain, this protein interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. CD340 has been shown to be involved in embryonic development and cancer progression, this protein is amplified in adenocarcinoma of the lung, some breast cancers, glioblastoma, gastric cancer, and ovarian carcinoma, where it functions as an oncogene. Overexpression of erbB2 in breast cancers has been shown to confer Taxol resistance and is a therapeutic target in a number of human cancers. The erbB2/HER-2 protein has been shown to interact with a large number of proteins, including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others. CD340 is extensively modified by tyrosine phosphoryation on multiple residues (Y1023, Y1139, Y1196, Y1221, Y1222, Y1248).

Pathways: Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Skeletal Muscle Fiber Development